| 梁少红,曾发凤,余丹,等.非奈利酮对慢性肾病非糖尿病IgA肾病患者血清Klotho、ROCK2、SFRP4水平的影响[J].安徽医药,待发表. |
| 非奈利酮对慢性肾病非糖尿病IgA肾病患者血清Klotho、ROCK2、SFRP4水平的影响 |
|
| 投稿时间:2026-09-17 录用日期:2026-11-17 |
| DOI: |
| 中文关键词: 非奈利酮 非糖尿病IgA肾病 Klotho ROCK2 SFRP4 |
| 英文关键词: |
| 基金项目:2025年卫健委科学技术(项目编号:gzwkj2025-040);2025年卫健委科学技术(项目编号:gzwkj2025-275) |
|
| 摘要点击次数: 27 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的 探讨非奈利酮联合氯沙坦钾对1~3期非糖尿病IgA肾病患者肾功能及血清Klotho、ROCK2、SFRP4水平的影响,分析该联合方案的临床疗效与用药安全性。方法 选取2023年1月—2024年8月本院收治的96例CKD1~3期非糖尿病IgA肾病患者,随机分为对照组(47例,单用氯沙坦钾)与联合治疗组(49例,非奈利酮联合氯沙坦钾),两组均规范治疗3个月。对比两组治疗前后肾功能、晨尿红细胞、UACR分层分布及血清Klotho、ROCK2、SFRP4表达,统计临床总有效率及不良反应发生率。结果 治疗前两组基线各项指标无统计学差异(P>0.05);治疗后两组eGFR升高,24h尿蛋白、SCr、BUN、CysC均降低,血清Klotho上升、ROCK2与SFRP4下降,UACR重度分层病例占比减少,且联合治疗组上述指标改善幅度均优于对照组(P<0.05)。对照组临床总有效率82.98%,联合治疗组97.96%,组间差异有统计学意义(P<0.05);对照组不良反应发生率14.29%,联合治疗组12.77%,二者对比无统计学差异(P>0.05),无严重不良事件发生。结论 非奈利酮联合氯沙坦钾可显著改善早中期非糖尿病IgA肾病患者肾功能,降低蛋白尿与血尿,降低重度微量白蛋白尿占比,上调肾脏保护性蛋白、抑制促纤维化因子表达,缓解肾脏氧化应激与纤维化进程,临床缓解率更高且耐受性良好,适合此类患者早期联合干预。 |
| 英文摘要: |
| Objective To investigate the effects of finerenone combined with losartan potassium on renal function and serum levels of Klotho, ROCK2, and SFRP4 in patients with non-diabetic IgA nephropathy at CKD stages 1–3, and to analyze the clinical efficacy and safety of this combination therapy. Methods A total of 96 patients with CKD stage 1–3 non-diabetic IgA nephropathy admitted to our hospital from January 2023 to August 2024 were randomly divided into control group (47 cases, losartan potassium monotherapy) and combined treatment group (49 cases, losartan potassium plus finerenone), with 3 months of standardized intervention. Renal function indicators, morning urine red blood cell count, UACR stratification and serum concentrations of Klotho, ROCK2, SFRP4 were detected before and after treatment; the overall clinical response rate and incidence of adverse reactions were recorded. Results No significant differences were found in all baseline indicators between the two groups before treatment (P>0.05). After treatment, eGFR increased, while 24-hour urinary protein, SCr, BUN, CysC and urine red blood cell count decreased; serum Klotho was upregulated, ROCK2 and SFRP4 were downregulated, and the proportion of patients with severe UACR declined. All improvements in the combined treatment group were superior to the control group (P<0.05). The overall clinical effective rate was 82.98% in the control group and 97.96% in the combined group (P<0.05). The adverse reaction rates were 14.29% and 12.77% respectively, without statistical difference (P>0.05), and no serious adverse events occurred during follow-up. Conclusion Finerenone combined with losartan potassium can significantly improve glomerular filtration function, reduce proteinuria and hematuria, lower the proportion of patients with severe microalbuminuria in patients with early-to-moderate non-diabetic IgA nephropathy. It upregulates renal protective protein and inhibits profibrotic factors, alleviating renal oxidative stress and interstitial fibrosis. The combined regimen achieves higher clinical remission rate with favorable tolerance, which is worthy of early combined intervention for such patients. |
|
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|